Sanofi-Aventis (SNY) After Genzyme Corp. (GENZ) Again in Merger Discussion
It was last August that French drug maker Sanofi-Aventis publicly disclosed that it had made an offer to buy Genzyme after approaching the company two months earlier in friendly merger discussions. The $18.5 billion bid represented a $69 per share offer, which at the time was at a nearly 40 percent premium to Genzyme’s share price before investors got wind of the merger talks and sent shares of GENZ surging north to the area of $70 in late July. Negotiations at that time ended without any terms being reached as Sanofi’s CEO, Christopher Viehbacher described discussions as being thwarted by…